• MDS Congress 2026 Session 1104 Evaluation Form

  • Therapeutic Plenary Session 1104

    Atypical Parkinsonism

    October 4, 2026

    16:00 - 17:30

  • Learning Objectives:

    1. Identify symptomatic treatments and the latest therapeutic developments in PSP
    2. Identify the symptomatic treatments and the latest therapeutic developments in MSA
    3. Summarize the multimodal, technology-assisted, and other non-pharmacological management strategies for patients with PSP and MSA

  • Session Evaluation

  • The session met its learning objectives
  • The content is relevant to my professional and / or scientific interests.
  • The quality of the education process (method of presentation and information provided) was satisfactory and appropriate.
  • The information provided will enhance my care of patients with Movement Disorders and / or advance my scientific understanding of Movement Disorders.
  • The overall session organization was satisfactory and appropriate.
  • I would recommend this session to a colleague.

  • Faculty Assessment

  • Huw Morris, United Kingdom

  • This speaker was able to effectively communicate the content of their presentation
  • The information was presented without commercial bias. The speaker did not discuss a single branded commercial product or service.

  • Junghwan Shin, Korea

  • This speaker was able to effectively communicate the content of their presentation
  • The information was presented without commercial bias. The speaker did not discuss a single branded commercial product or service.

  • Jori Fleisher, USA

  • This speaker was able to effectively communicate the content of their presentation
  • The information was presented without commercial bias. The speaker did not discuss a single branded commercial product or service.
  • The following category best describes your current major professional activity (choose one):

  • Should be Empty: